Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiya Horimoto

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
Annals of Surgical Oncology|June 26, 2026
Cyclin E1 Expression Predicts Poorer Outcome in HER2-positive Breast Cancer with Residual Disease after Neoadjuvant ChemotherapyYuko Ueki, Yoshiya Horimoto, Men Yuan, et al.
Journal of Clinical Pathology|June 11, 2015
Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patientsYoshiya Horimoto, Atsushi Arakawa, Masahiko Tanabe, et al.
Breast Cancer (Tokyo, Japan)|February 29, 2020
Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancerMayu Myojin, Yoshiya Horimoto, Mayuko Ito, et al.
Breast Cancer (Tokyo, Japan)|July 20, 2025
Breast tumors with intermediate ER expression differ biologically from ER-low tumors and exhibit a more favorable prognosisYuko Ueki, Yoshiya Horimoto, Kazuharu Harada, et al.
Cancer Diagnosis & Prognosis|May 4, 2026
Current Status and Challenges of <i>BRCA1</i> and <i>BRCA2</i> Genetic Testing for Hereditary Breast and Ovarian Cancer in JapanKayono Onishi, Yoshiya Horimoto, Kazuyo Kiribayashi, et al.
Oncology Letters|November 30, 2023
Clinicopathological and molecular pathological characteristics in tamoxifen‑related endometrial cancerHarumi Saeki, Yoshiya Horimoto, May Thinzar Hlaing, et al.
Anticancer Research|January 31, 2021
Biological and Clinicopathological Implications of Beta-3-N-acetylglucosaminyltransferase 8 in Triple-negative Breast CancerMisato Okazaki, Kaoru Mogushi, Kaori Denda-Nagai, et al.
The American Journal of Surgical Pathology|June 14, 2019
Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene AmplificationYoshiya Horimoto, Takako Terao, Yuko Tsutsumi, et al.
Clinical & Experimental Metastasis|January 9, 2024
Glycosylation profiles of breast cancer cells may represent clonal variations of multiple organ metastasesYoshiya Horimoto, May Thinzar Hlaing, Harumi Saeki, et al.
Breast Cancer Research : BCR|September 30, 2025
Hsa-miR-155-5p expression in primary breast tissue may have the potential for prediction of breast cancer brain recurrence: results from the multi-institutional exploratory cohort studyYoichi Koyama, Masako Muguruma, Yoshiya Horimoto, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
Annals of Surgical Oncology|June 26, 2026
Cyclin E1 Expression Predicts Poorer Outcome in HER2-positive Breast Cancer with Residual Disease after Neoadjuvant ChemotherapyYuko Ueki, Yoshiya Horimoto, Men Yuan, et al.
Journal of Clinical Pathology|June 11, 2015
Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patientsYoshiya Horimoto, Atsushi Arakawa, Masahiko Tanabe, et al.
Breast Cancer (Tokyo, Japan)|February 29, 2020
Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancerMayu Myojin, Yoshiya Horimoto, Mayuko Ito, et al.
Breast Cancer (Tokyo, Japan)|July 20, 2025
Breast tumors with intermediate ER expression differ biologically from ER-low tumors and exhibit a more favorable prognosisYuko Ueki, Yoshiya Horimoto, Kazuharu Harada, et al.
Cancer Diagnosis & Prognosis|May 4, 2026
Current Status and Challenges of <i>BRCA1</i> and <i>BRCA2</i> Genetic Testing for Hereditary Breast and Ovarian Cancer in JapanKayono Onishi, Yoshiya Horimoto, Kazuyo Kiribayashi, et al.
Oncology Letters|November 30, 2023
Clinicopathological and molecular pathological characteristics in tamoxifen‑related endometrial cancerHarumi Saeki, Yoshiya Horimoto, May Thinzar Hlaing, et al.
Anticancer Research|January 31, 2021
Biological and Clinicopathological Implications of Beta-3-N-acetylglucosaminyltransferase 8 in Triple-negative Breast CancerMisato Okazaki, Kaoru Mogushi, Kaori Denda-Nagai, et al.
The American Journal of Surgical Pathology|June 14, 2019
Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene AmplificationYoshiya Horimoto, Takako Terao, Yuko Tsutsumi, et al.
Clinical & Experimental Metastasis|January 9, 2024
Glycosylation profiles of breast cancer cells may represent clonal variations of multiple organ metastasesYoshiya Horimoto, May Thinzar Hlaing, Harumi Saeki, et al.
Breast Cancer Research : BCR|September 30, 2025
Hsa-miR-155-5p expression in primary breast tissue may have the potential for prediction of breast cancer brain recurrence: results from the multi-institutional exploratory cohort studyYoichi Koyama, Masako Muguruma, Yoshiya Horimoto, et al.
Pageof 13